Ehv with inactivated ul18 and/or ul8
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsRamesh Koukuntla, Jana M. Larsen, Robert Barry Mandell, Luka N. Pelz, Eric Marlin Vaughn
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of (vector) vaccines, and especially to novel EHV's having an inactivation of UL18 and/or UL8. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.
Claims21
A replication deficient Equid Alphaherpesvirus (EHV) vector comprising an inactivation of UL18 and/or UL8.
A cell line comprising a plasmid comprising an expression cassette comprising UL8 and/or UL18 of EHV or functional parts thereof, wherein the cell line is expressing UL8 and/or UL18 or functional parts thereof.
Dependencies are inferred from the claim text.